E. Gouda

Clinical utility of repurposing a short course of hepatitis C drugs for COVID19. A randomized controlled study

B. Eysa, E. Reyad, M. Yakoot, 2022, medRxiv.

Predictive Value of miR-146a rs2431697 Polymorphism to Myelofibrosis Progression in Patients with Myeloproliferative Neoplasm

S. Aref, Doaa Atia, E. Gouda, 2021, Asian Pacific journal of cancer prevention : APJCP.

DNA Repair Genes Polymorphisms: Impact on Acute Myeloid Leukemia Patients Outcome

S. Aref, Nadia El Menshawy, E. Gouda, 2022, Asian Pacific journal of cancer prevention : APJCP.

Circulating CXCL13 could be served as a biomarker for chronic lymphocytic leukemia severity.

S. Aref, Ahmed M Ramez, Doaa Atia, 2021, Cancer biomarkers : section A of Disease markers.

Predictive Value of Interferon γ Receptor Gene Polymorphisms for Hepatocellular Carcinoma Susceptibility

S. Aref, Eman Adel, E. Gouda, 2021, Asian Pacific journal of cancer prevention : APJCP.

COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study

A. Alsaeedi, Fatma Alhuraish, M. Askar, 2020, International Journal of Infectious Diseases.

Prognostic Value of Serum CD200 Concentrations in Chronic Lymphocytic Leukemia

S. Aref, E. Gouda, M. Ayed, 2023, Asian Pacific journal of cancer prevention : APJCP.

Soluble bone marrow CXCL-10: a novel biomarker for B-acute lymphoblastic leukemia’s response to induction chemotherapy

S. Aref, A. Aref, Ahmed Al Tantawy, 2022, Comparative Clinical Pathology.